See the DrugPatentWatch profile for Letairis
What is Letairis, and what does it treat?
Letairis is a prescription medicine used to treat pulmonary arterial hypertension (PAH) to help improve exercise capacity and symptoms. It contains the active ingredient ambrisentan [1].
How does Letairis work?
Letairis blocks the effects of endothelin, a naturally occurring substance that can tighten blood vessels and worsen PAH. By inhibiting endothelin signaling, it helps reduce blood vessel constriction in the lungs [1].
How is Letairis usually taken?
Letairis is taken by mouth once daily as prescribed by a clinician. The exact dose depends on the patient and treatment plan [1].
What are the most common side effects people ask about?
Commonly reported side effects include headache, flushing, swelling (edema), and nasal congestion or sinus symptoms. Patients should discuss side effects with their prescriber, especially if swelling worsens [1].
What serious risks come with Letairis?
Letairis can cause serious harm to an unborn baby, so pregnancy must be avoided during treatment. It also requires careful monitoring and adherence to a pregnancy prevention program and related testing requirements [1].
Does Letairis interact with other medicines?
Letairis can interact with other drugs, including medicines that affect liver enzymes and certain therapies used for PAH. Patients should provide a full list of medications (including over-the-counter drugs and supplements) to their clinician before starting [1].
Is Letairis the same as other PAH medicines?
Letairis (ambrisentan) is not the same as PAH medicines with different mechanisms, such as sildenafil or tadalafil (PDE-5 inhibitors), selexipag (a prostacyclin pathway medicine), or endothelin receptor antagonists in the same class. Clinicians choose based on PAH severity, patient factors, and treatment goals [1].
What monitoring is required while on Letairis?
Because of safety requirements—especially pregnancy risk and liver-related concerns—patients typically need scheduled monitoring as directed by their healthcare team [1].
Where can I find official information?
You can review the prescribing information and safety guidance through the product’s official documentation [1].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202379